Drug Trial Radar · NCT02923986
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Last checked: Nov 19, 2026Latest source record: May 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 1, 2017
Primary completion
May 27, 2020
Study completion May 27, 2020
Sponsor
- Lead sponsor
- Bio-Path Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) including chronic phase patients who have failed initial tyrosine kinase inhibitor (TKI) therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.
Conditions
- Chronic Myelogenous Leukemia, Ph1-Positive
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
BP1001 (varying dose)Drug
BP1001 (varying dose)
BP1001 (fixed dose)Drug
BP1001 (fixed dose)
DasatinibDrug
Dasatinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteriaTime frame: 240 days
- Maximum Tolerated Dose of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteriaTime frame: 240 days
- Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood countsTime frame: 240 days
- Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsyTime frame: 240 days
- Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsyTime frame: 240 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.